We cover new discoveries to improve healthcare out of Switzerland that could have a global impact.
More
The race to launch a pill for weight loss
This content was published on
Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of obesity medicine.
When diagnosing a disease does more harm than good
This content was published on
Switzerland has the highest number of MRI scanners per person in Europe. But more screening doesn’t always lead to better health outcomes.
Can Saudi Arabia’s billions unlock the secrets to a longer, healthier life?
This content was published on
Longevity has been an underfunded area of biotech research but that is changing thanks to an unlikely source: Saudi Arabia.
Global concern over measles is rising. Should Switzerland worry?
This content was published on
Measles is making a global comeback. In Switzerland, a crisis is unlikely – but authorities warn a strong vaccination rate remains crucial.
This content was published on
Nearly 30 years ago an academic paper wrongly linked autism to a measles vaccine. The impacts are still being felt today.
Novartis bets on ageing as next frontier in drug development
This content was published on
Swiss pharma giant Novartis is diving into research on ageing to tap the growing market for drugs that help keep older adults healthy.
This content was published on
People have come to Switzerland for centuries in search of the fountain of youth. How did the country become a magnet for longevity seekers?
Longevity clinics: modern-day snake oil or the key to healthy ageing?
This content was published on
Scientists have yet to find the elixir of life but this hasn’t stopped longevity clinics from selling treatments, pills and gadgets that claim to slow ageing.
‘It’s political’: why some people refuse to have a smartphone
This content was published on
Almost two decades after the first iPhone, not everyone is ready to go fully digital. We talk to three people sceptical of the always-online life.
Digital democracy: will Swiss signature scandal pave way for e-collecting?
This content was published on
It remains to be seen whether the signature scam will bring about the digitalisation of direct democracy in Switzerland. An overview of the situation.
This content was published on
As Facebook and Instagram relax content restrictions, the commitment of volunteers who push back against hate is becoming more crucial than ever.
Electric touch: neurostimulation’s comeback in psychiatry
This content was published on
Faced with a lack of breakthroughs in treating mental health disorders, older methods such as electrical-based therapies are experiencing a revival.
Digital citizens could shake up democracy in Switzerland and beyond
This content was published on
Leading experts in medicine and business are pinning their hopes on digital twins. Two economists have a bold proposal that could reshape democracy.
How private equity oversees the ethics of drug research
This content was published on
Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety.
How a clash with Roche exposed cracks in Swiss drug pricing system
This content was published on
Switzerland’s new process to speed up patient access to the latest drugs hit its first major hurdle in a clash with Roche.
Chinese biotechs eye Swiss collaboration as relations with US sour
This content was published on
With growing uncertainty in the US, Chinese companies are swooping in to present themselves as stable, open partners to the Swiss biotech sector.
Electric touch: neurostimulation’s comeback in psychiatry
This content was published on
Faced with a lack of breakthroughs in treating mental health disorders, older methods such as electrical-based therapies are experiencing a revival.
This content was published on
Gene therapy companies have faced numerous setbacks over the last few years. What will it take for gene therapies to fulfill their promise?
Discovering ancient microorganisms inside Swiss glaciers
This content was published on
Follow a team of scientists on the Rhône glacier as they hunt for new – and potentially beneficial – microorganisms which are increasingly being released from the melting ice.
Explainer: Switzerland gears up for driverless transport era
This content was published on
What impact will autonomous transport have in Switzerland, and can we expect to see a flood of driverless cars any time soon?
Why a prospering Irish Nestlé factory is closing down
This content was published on
China’s baby boom enriched a small Irish town where a Nestlé factory made formula for Chinese newborns. Then a baby bust unraveled it all. Or so it seemed.
How private equity oversees the ethics of drug research
This content was published on
Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety.
How a clash with Roche exposed cracks in Swiss drug pricing system
This content was published on
Switzerland’s new process to speed up patient access to the latest drugs hit its first major hurdle in a clash with Roche.
When diagnosing a disease does more harm than good
This content was published on
Switzerland has the highest number of MRI scanners per person in Europe. But more screening doesn’t always lead to better health outcomes.
Can Saudi Arabia’s billions unlock the secrets to a longer, healthier life?
This content was published on
Longevity has been an underfunded area of biotech research but that is changing thanks to an unlikely source: Saudi Arabia.
Global concern over measles is rising. Should Switzerland worry?
This content was published on
Measles is making a global comeback. In Switzerland, a crisis is unlikely – but authorities warn a strong vaccination rate remains crucial.
This content was published on
Nearly 30 years ago an academic paper wrongly linked autism to a measles vaccine. The impacts are still being felt today.
Novartis bets on ageing as next frontier in drug development
This content was published on
Swiss pharma giant Novartis is diving into research on ageing to tap the growing market for drugs that help keep older adults healthy.
Chinese biotechs eye Swiss collaboration as relations with US sour
This content was published on
With growing uncertainty in the US, Chinese companies are swooping in to present themselves as stable, open partners to the Swiss biotech sector.
The Basel researcher whose work triggered a longevity revolution
This content was published on
Basel-based scientist Michael Hall’s discovery of the gene Target of Rapamycin has fuelled one of the fastest growing trends – longevity.
This content was published on
People have come to Switzerland for centuries in search of the fountain of youth. How did the country become a magnet for longevity seekers?
Longevity clinics: modern-day snake oil or the key to healthy ageing?
This content was published on
Scientists have yet to find the elixir of life but this hasn’t stopped longevity clinics from selling treatments, pills and gadgets that claim to slow ageing.
Living longer: What do you think about the longevity trend?
The longevity market is booming thanks in part to advances in the science of ageing. What do you think of the idea of significantly extending human lifespan?
In Switzerland more people are being referred to electrical therapies or psychedelic-assisted psychotherapy. Are there similar approaches where you live?
Electric touch: neurostimulation’s comeback in psychiatry
This content was published on
Faced with a lack of breakthroughs in treating mental health disorders, older methods such as electrical-based therapies are experiencing a revival.
This content was published on
Gene therapy companies have faced numerous setbacks over the last few years. What will it take for gene therapies to fulfill their promise?
‘It’s political’: why some people refuse to have a smartphone
This content was published on
Almost two decades after the first iPhone, not everyone is ready to go fully digital. We talk to three people sceptical of the always-online life.
What the Swiss don’t know about sexually transmitted infections
This content was published on
Many Swiss are not that savvy about sexually transmitted infections. Even so, a programme to inform people about STIs is being cut.
Digital democracy: will Swiss signature scandal pave way for e-collecting?
This content was published on
It remains to be seen whether the signature scam will bring about the digitalisation of direct democracy in Switzerland. An overview of the situation.
Switzerland no longer wants to foot the bill for ‘suicide tourism’
This content was published on
In Switzerland, all deaths through assisted suicide must be followed by a medical and legal investigation. This entails considerable costs for the state.
This content was published on
As Facebook and Instagram relax content restrictions, the commitment of volunteers who push back against hate is becoming more crucial than ever.
After the first ‘Sarco pod’ death, will Switzerland introduce stricter rules for assisted suicide?
This content was published on
The first death to come about using the Sarco capsule has reignited debate on whether assisted dying should be more tightly regulated in Switzerland.
Digital citizens could shake up democracy in Switzerland and beyond
This content was published on
Leading experts in medicine and business are pinning their hopes on digital twins. Two economists have a bold proposal that could reshape democracy.
Discovering ancient microorganisms inside Swiss glaciers
This content was published on
Follow a team of scientists on the Rhône glacier as they hunt for new – and potentially beneficial – microorganisms which are increasingly being released from the melting ice.
